Pressmeddelande

Arctic Bioscience – Treatment start for 519 patients in the HeROPA-study

Cision Publicerad: 28 Feb 17:08

With reference to the stock exchange announcement from 17. January 2024 which reported that the HeROPA phase IIb clinical trial in mild-to-moderate psoriasis was fully recruited with the planned 519 patients, Arctic Bioscience are pleased to report that 519 patients are now dosed with the Investigational Medicinal Product HRO350 or placebo. After all patients have been dosed for 6 months, the primary endpoint will be read out.

The HeROPA trial is randomized, double blind and placebo controlled, investigating the efficacy and safety of the novel, oral drug candidate HRO350 for the treatment of mild-to-moderate psoriasis. The HeROPA trial is ongoing in 5 countries in Europe; UK, Germany, Poland, Finland and Norway.

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Nyheter om Arctic Bioscience

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!